A detailed history of China Universal Asset Management Co., Ltd. transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 4,176 shares of MDGL stock, worth $1.45 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares
4,176
Previous 2,504 66.77%
Holding current value
$1.45 Million
Previous $701,000 26.39%
% of portfolio
0.1%
Previous 0.1%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$212.22 - $292.96 $354,831 - $489,829
1,672 Added 66.77%
4,176 $886,000
Q2 2024

Jul 19, 2024

SELL
$193.33 - $291.99 $250,749 - $378,711
-1,297 Reduced 34.12%
2,504 $701,000
Q1 2024

Apr 29, 2024

BUY
$171.37 - $283.23 $258,597 - $427,394
1,509 Added 65.84%
3,801 $1.02 Million
Q4 2023

May 21, 2024

SELL
$120.4 - $237.13 $181,683 - $357,829
-1,509 Reduced 39.7%
2,292 $530,000
Q4 2023

Jan 23, 2024

BUY
$120.4 - $237.13 $219,609 - $432,525
1,824 Added 389.74%
2,292 $530,000
Q3 2023

May 21, 2024

BUY
$146.04 - $225.78 $33,297 - $51,477
228 Added 95.0%
468 $68,000
Q3 2023

Oct 30, 2023

BUY
$146.04 - $225.78 $33,297 - $51,477
228 Added 95.0%
468 $68,000
Q2 2023

May 21, 2024

SELL
$203.88 - $312.0 $1,223 - $1,872
-6 Reduced 2.44%
240 $55,000
Q2 2023

Jul 27, 2023

SELL
$203.88 - $312.0 $1,223 - $1,872
-6 Reduced 2.44%
240 $55,000
Q1 2023

May 21, 2024

BUY
$231.06 - $307.08 $16,636 - $22,109
72 Added 41.38%
246 $59,000
Q1 2023

Apr 27, 2023

BUY
$231.06 - $307.08 $16,636 - $22,109
72 Added 41.38%
246 $60,000
Q4 2022

May 21, 2024

SELL
$58.39 - $296.54 $211,780 - $1.08 Million
-3,627 Reduced 95.42%
174 $50,000
Q4 2022

Jan 31, 2023

SELL
$58.39 - $296.54 $141,537 - $718,812
-2,424 Reduced 93.3%
174 $51,000
Q3 2022

Oct 21, 2022

BUY
$60.57 - $79.51 $157,360 - $206,566
2,598 New
2,598 $169,000

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.94B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.